Boehringer Ingelheim GmbH dpp-4 Pages on BioPortfolio:

BioPortfolio - Boehringer Ingelheim GmbH dpp-4
Boehringer Ingelheim GmbH dpp-4 Pages on BioPortfolio: ... BioPortfolio - Boehringer Ingelheim GmbH dpp-4 18.16.1 Saxagliptin 18.17 Research Pipeline for
...
http://www.bioportfolio.com/search/Boehringer_Ingelheim_GmbH...

BioPortfolio - saxagliptin
BioPortfolio - Boehringer Ingelheim GmbH dpp-4 18.16.1 Saxagliptin 18.17 Research . ... BioPortfolio - ohio postcodes BioPortfolio - saxagliptin 18 Jun
...
http://www.bioportfolio.com/search/saxagliptin.html...

BioPortfolio - Boehringer Ingelheim Pharma GmbH & Co. KG
KG | Boehringer Ingelheim Pharma GmbH | Boehringer Ingelheim GmbH dpp-4 | Boehringer Ingelheim profile | Boehringer Ingelheim Pharma GmbH Co KG | BI
Pharma ...
http://www.bioportfolio.com/biocorporate/20061-Boehringer_In...

BioPortfolio - Ondero Boehringer
BioPortfolio - Boehringer Ingelheim GmbH dpp-4 IsoTech Design Inc · ONDERO BI 1356 · Boehringer Ingelheim Pharma GmbH & Co. ... BioPortfolio - jencons vwr ...
http://www.bioportfolio.com/search/Ondero_Boehringer.html...

BioPortfolio - Boehringer-Ingelheim dpp
Boehringer-Ingelheim dpp - BioPortfolio. ... BioPortfolio - Boehringer Ingelheim GmbH dpp-4 18.16.1 Saxagliptin 18.17 Research Pipeline for Boehringer . ...
http://www.bioportfolio.com/search/Boehringer-Ingelheim_dpp....

Results from other life science and pharmaceutical sites:

Microsoft PowerPoint - 04 Mark_Dugi Diabetes DPP4 SGLT2 FINAL ...
17 Oct 2008 ... Prevalence drastically increasing worldwide. Inhibition of DPP-4. (Dipeptidyl peptidase 4). Boehringer Ingelheim investigates modern ...
http://www.boehringer-ingelheim.com/corporate/news/presspack...

Treatments - © Boehringer Ingelheim, Oct. 2008 – International R&D ...
type 2 diabetes are DPP-4 and SGLT-2 inhibitors, currently under development by Boehringer Ingelheim. 1. DPP-4 Inhibitors ...
http://www.boehringer-ingelheim.com/corporate/news/presspack...

Boehringer Ingelheim News -
Boehringer Ingelheim GmbH Science & Technology Communications Julia Meyer- Kleinmann Binger Strasse 173 55216 Ingelheim am Rhein GERMANY ...
http://www.boehringer-ingelheim.com/corporate/news/press_rel...

News in brief : Article : Nature Reviews Drug Discovery
Phase IIa studies were also presented for the novel DPP4 inhibitor BI 1356 ( Boehringer Ingelheim). DPP4 inhibitors block the degradation of glucagon-like
...
http://www.nature.com/nrd/journal/v7/n7/full/nrd2635.html...

History - © Boehringer Ingelheim, Oct. 2008 – International R&D ...
14 Oct 2008 ... o The U.S. Food & Drug Administration approved the first DPP-4 ... 2008: Boehringer Ingelheim announces the Company’s commitment to bring ...
http://www.boehringer-ingelheim.com/corporate/news/presspack...

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-meth...[J Pharmacol ...
Boehringer Ingelheim Pharma GmbH and Co. KG, Department of Metabolic Diseases Research, ... BI 1356 inhibited DPP-4 activity in vitro with an IC(50) of ...
http://www.ncbi.nlm.nih.gov/pubmed/18223196...

From Curiosity to Discovery: Boehringer Ingelheim's Pipeline ...
Boehringer Ingelheim's Investigational Compound in Development for the ... such as the inhibition of DPP-4 (dipeptidyl peptidase-4 inhibitors) and ...
http://biz.yahoo.com/prnews/081017/3763462en_public.html?.v=...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.